Laboratories can benefit from using hydrolysis in urine drug testing because it "increases the parent drug concentration of therapeutics that are primarily metabolized to glucuronide or sulfate metabolites," writes Kamisha Johnson-Davis, medical director of clinical toxicology at ARUP Laboratories.
She also cites some of the procedure's limitations, such as increased sample preparation time and the fact that acid could degrade benzodiazepine and opioid drugs.
Swedish investigators found that treatment with decidua stromal cells derived from the placentas of healthy mothers was associated with improvements in survival in a study of 38 patients with severe acute graft-versus-host disease who underwent hematopoietic stem cell transplantation. Cells prepared using human serum albumin were more effective than those prepared with active human AB plasma, according to the study in the journal Stem Cells Translational Medicine.
Spread of the hemorrhagic disease Lassa fever in Nigeria has resulted in 365 confirmed cases and 114 deaths. The country's CDC has reducing waiting times for tests by adding a laboratory in Ebonyi state.
Baxter has purchased Mallinckrodt Pharmaceuticals' hemostat and sealant assets for $153 million. Potential milestone payments are included in the deal.
A 685-patient, 33-site trial published in the journal CHEST found Integrated Diagnostics' Xpresys Lung 2 test, also known as XL2, can detect early-stage cancer indicators LG3BP and C163A blood plasma proteins in 8mm to 30mm lung nodules. The test, which allows protein measurement to be combined with five standard-of-care clinical factors into a single risk assessment, demonstrated an error rate of 3%, compared with the 45% misclassification of cancers in standard of care.
A report in the CDC's Morbidity and Mortality Weekly Report documents 10 cases of yellow fever among unvaccinated travelers coming back from Brazil, four of whom died. The CDC has updated its recommendations for travel vaccinations to include popular tourist destinations in Brazil.
Prior chemotherapy appears to limit the expansion and efficacy of chimeric antigen receptor T cells in children with certain types of cancer, according to research reported in advance of the annual meeting of the American Association for Cancer Research. Specific types of chemotherapeutic drugs, such as doxorubicin and cyclophosphamide, were associated with depleted T cell energy reserve, a sign of poor clinical performance, and efficacy appears to be influenced by the fuel pathways used by T cells. The findings could lead to alternate approaches "to make sure that we make a highly functional CAR T-cell product, not only for kids with leukemia but also for potentially solid-tumor CARs, as we try to develop those in the future," said Dr. David Barrett of Children's Hospital of Philadelphia.
Primary endpoints for safety and tolerability were met in Inovio Pharmaceuticals' Phase I clinical study evaluating its DNA immunotherapy candidate INO-1800 as a standalone treatment or combined with INO-9112 among 90 subjects with chronic hepatitis B infection. More data from the study will be submitted for publication and future medical conference presentation.
Cesca Therapeutics announced that a licensing agreement was signed between its subsidiary ThermoGenesis and IncoCell Tianjin to provide cellular processing services for chimeric antigen receptor T-cell therapies on a contract development and manufacturing basis to several Asia Pacific countries. Cesca will receive a percentage from IncoCell's gross contract development revenues.
A 10-year partnership deal, valued at $40 million in upfront payments and up to $10 million worth of ongoing royalties and milestones, was reached by Qiagen with its longtime customer, Natera, calling for Natera to create cell-free noninvasive prenatal tests for use on Qiagen's GeneReader NGS System. The assays, which will build on Qiagen's PAXgene blood cell-free DNA collection and sample processing technology, will identify if a baby is at an increased risk for common genetic conditions.